Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects
A Single-center, Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics After Single-dose Administration of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects
Sponsor: Viatris Innovation GmbH
Listed as NCT04052360, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Viatris Innovation GmbH, it has been updated 7 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Oct 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
May 2020 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
Dec 2019 — May 2020 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2019 — Dec 2019 [monthly]
Recruiting PHASE1
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Viatris Innovation GmbH
For direct contact, visit the study record on ClinicalTrials.gov .